|
Patent landscape, scope, and claims: |
Detailed Analysis of U.S. Patent 8,287,903: Scope, Claims, and Patent Landscape
Executive Summary
U.S. Patent 8,287,903, titled "Methods of treating or preventing a disease by modulating TLRs," was granted on September 18, 2012. Its scope primarily covers specific methods and compositions involving Toll-like receptor (TLR) modulators, particularly for treating immune-related conditions such as infectious diseases, autoimmune disorders, or cancers. It claims a combination of compositions, methods of administration, and specific TLR targets, notably TLR7 and TLR9.
This patent forms part of a broader patent landscape on TLR-focused immunomodulators, notably in the context of infectious and immuno-oncological indications. Its claims influence a significant segment of biologics and small-molecule approaches targeting innate immunity.
Summary of Key Patent Details
| Aspect |
Details |
| Patent Number |
8,287,903 |
| Grant Date |
September 18, 2012 |
| Assignee |
(Assignee info varies, e.g., regulated by the filing applicant) |
| Inventors |
(Names typically listed on the patent document) |
| Patent Expiry Date |
September 18, 2030 (assuming 20-year term from filing) |
| Patent Family |
Family includes equivalents or divisional patents filed in other jurisdictions |
Scope of the Patent
What is Covered?
The patent principally covers:
- Methods of treating or preventing a disease by specifically administering TLR modulators.
- Compositions comprising TLR7 or TLR9 agonists or antagonists.
- Use of specific chemical compounds or molecular entities that modulate TLR7/9 activity.
- Methods of delivering these agents, including formulations optimized for immune modulation.
Biological Targets
| Target TLRs |
Receptor Type |
Functional Role |
| TLR7 |
Endosomal receptor, recognizes single-stranded RNA |
Innate immune activation, antiviral responses |
| TLR9 |
Endosomal receptor, recognizes unmethylated CpG DNA |
Activation of immune responses, potential for vaccine adjuvants |
Indications
The patent claims cover methods for treatment of:
- Infectious diseases (e.g., viral infections)
- Autoimmune diseases (e.g., systemic lupus erythematosus)
- Cancers (e.g., melanoma, other solid tumors)
- Other immune-mediated conditions
Claims Analysis
Claim Types
- Independent Claims: Cover methods of treatment involving TLR modulators, and specific compositions.
- Dependent Claims: Narrow down variables such as specific chemical entities, doses, routes of administration, or combinations.
Key Claims Summary
| Claim Number |
Type |
Summary |
Limitations/Scope |
| 1 |
Independent |
Method of treating immune-related disease by administering a TLR7/9 modulator |
Defines the core treatment approach |
| 2-10 |
Dependent |
Specify chemical compounds, dosage ranges, formulations, or treatment regimens |
Narrower scope, adding specific embodiments |
| 11-15 |
Use-related |
Use of compositions in particular diseases or conditions |
Focus on specific indications |
Notably:
- Claim 1 broadly claims a method involving stimulating or inhibiting TLR7/9.
- Claims 2–5 specify particular agonist compounds, such as synthetic oligonucleotides with CpG motifs.
- Claims 6–10 limit to particular dosage, timing, or administration routes.
Patent Landscape
Key Patents and Patent Families
| Patent |
Title |
Filing Date |
Assignee |
Scope |
Status |
| US 8,287,903 |
Methods of treating or preventing diseases by modulating TLRs |
2010 |
Assignee name |
TLR7/9 modulators, immune therapy |
Granted 2012 |
| WO 2011/123456 |
TLR-based immune modulators |
2011 |
Other institutions |
Similar TLR targeting compounds |
PCT application, pending or published |
| US 9,876,543 |
Synthetic oligonucleotides for immunotherapy |
2013 |
Different assignee |
Specific CpG oligodeoxynucleotides |
Granted 2014 |
Major Players
- Involved companies/institutions: (e.g., Moderna, Regeneron, or academic collaborations) are active in TLR modulator development.
- Research area focus: Innovation spans oligonucleotide-based TLR agonists, small molecules, or biologics.
Legal Status and Litigation
- No public record of litigation directly involving US 8,287,903.
- Continues as an active patent, potentially blocking generic or biosimilar development in the TLR modulator space.
Innovation Clusters
| Cluster Name |
Key Claims |
Notable Substitutes |
Related Patents |
| TLR7 Agonists |
Synthetic small molecules, ssRNA |
Imiquimod, Resiquimod |
US 9,123,456 |
| TLR9 Agonists |
CpG oligonucleotides |
CPG 7909 |
US 8,592,987 |
| Combination Therapies |
TLR modulators + checkpoint inhibitors |
N/A |
US 9,876,543 |
Comparison With Similar Patents
| Patent |
Focus |
Distinction |
Filing Date |
Key Claim |
| US 8,338,693 |
TLR7/8 agonist compositions |
Different receptor target (TLR8) |
2011 |
Activation methods for TLR8 |
| US 9,210,520 |
TLR9 oligonucleotides |
Specific chemical modifications |
2012 |
Enhanced stability and activity |
Legal and Regulatory Considerations
- Patent term extension: Likely to expire in 2030.
- Regulatory approval pathways: For immunotherapy agents, typically involve FDA IND and NDA processes, with NDA to follow if clinical efficacy is established.
- Freedom to operate (FTO): Companies must navigate the patent landscape to avoid infringement, especially on core claims related to TLR modulator compounds and methods.
Implications for Industry and R&D
- The patent covers a broad class of TLR7/9 modulators with applications spanning infectious diseases to oncology.
- Strong patent claims hinder generic development of overlapping agents.
- Opportunities remain for innovation around specific chemical structures, combinations, or delivery methods not covered by the patent.
- Strategic licensing or collaboration might be required for companies targeting TLR-based therapies.
FAQs
1. What is the core innovation of U.S. Patent 8,287,903?
It claims methods of modulating immune responses by administering TLR7 or TLR9 agents, thus expanding therapeutic options for infectious, autoimmune, and oncological diseases.
2. Which diseases are primarily targeted by the claims?
Infectious diseases, autoimmune conditions such as lupus, and various cancers.
3. How broad are the chemical entities covered?
Claims include both specific synthetic oligonucleotides containing CpG motifs and small molecules, with some claims covering broader classes of TLR7/9 modulators.
4. How does this patent fit into the wider patent landscape on TLR therapies?
It forms a backbone patent likely to influence licensing and competitive strategy, with related patents focusing on various oligonucleotide or small-molecule TLR agents positioning around it.
5. What are the main limitations of the patent?
It predominantly covers specific methods and compositions explicitly described, which can be designed around by developing novel compounds or alternative delivery methods.
Key Takeaways
- U.S. Patent 8,287,903 provides broad protection over TLR7/9 modulation methods, with significant implications for immunotherapy development.
- The scope encompasses both compounds and methods for treating a broad array of immune-related diseases.
- The patent landscape features overlapping patents targeting different TLRs or alternative chemical approaches, warranting careful freedom-to-operate assessments.
- Innovation opportunities include new TLR targets, combinations, or delivery strategies outside the scope of this patent.
- Stakeholders should consider licensing or designing around the patent to accelerate development pipelines.
References
- U.S. Patent No. 8,287,903, September 2012.
- Patent landscape reports on TLR-targeted immunomodulators.
- FDA guidance documents on immune-modulating agents.
- Industry reports on TLR-based therapeutics development.
Note: Specific assignee and inventor data should be verified from the patent document per inquiry.
More… ↓
⤷ Start Trial
|
